IDWeek, October 2-6, 2013, San Francisco

Conference Reports for NATAP


ID Week, October 2-6, 2013, San Francisco

	ID Week 2012: Hepatitis C - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13) ID Week 2103: Polypharmacy in HIV - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13) ID Week 2013: Co-morbidities - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13) ID Week 2013: Antiretroviral Therapy - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13) Acute HCV Treatment/HIV+ MSM/HCV Screening/New HCV Therapies: "Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus" - (10/16/13) Polypharmacy in HIV: "Differences in calculated adherence rates of ART and non-ART medications among HIV positive veterans" - (10/16/13) Entecavir Versus Tenofovir in Treatment-Naive Chronic Hepatitis B Patients: Third Year Results of a Real World Study - (10/11/13) (CDC) Differences in Demographic, Behavioral and Clinical Characteristics between HCV Mono-infected and HCV/HIV Co-infected Adults in Outpatient Primary Care - (10/11/13) Clinicians May Overlook CD4 Percent in HIV+ When Deciding on PCP Prophylaxis - Written by Mark Mascolini - (10/11/13) Barriers to Effective Antenatal Hepatitis C Virus (HCV) Screening - (10/11/13) Effects of aging and antiretroviral therapy on B Cell phenotypes in HIV infected subjects - (10/11/13) (72% of women had Vit D Deficiency) Vitamin D supplementation increases Vitamin D levels but does not improve inflammatory markers in HIV Infected Women; a Chicago Women's Interagency HIV study (WIHS) study - (10/11/13) Metabolic, Bone, Renal, Inflammatory and Lipodystrophic Marker Analysis in INROADS, a Multicenter, Single-Arm, Open-Label Study of a Once-Daily Nucleoside/tide-Sparing Regimen of Etravirine (ETR) and Darunavir/Ritonavir (DRV/r) as Dual Therapy in Early Treatment-Experienced Subjects - (10/11/13) HIV TREATMENT CASCADE AMONG TRANSGENDER WOMEN IN A SAN FRANCISCO RESPONDENT DRIVEN SAMPLING STUDY - (10/11/13) Hospitalization among Persons with Chronic Hepatitis C Virus Infection in the United States: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 - (10/11/13) Mortality among Persons in Care with Hepatitis C Virus Infection-Chronic Hepatitis Cohort Study (CHeCS), 2006 -2010: HCV deaths grossly Underreported mortality rate 12 times higher than the general population, average age of death is 59 for HCV & 74 for general population, a 15 year difference - (10/11/13) SPIRIT: Simplification to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Maintains HIV-1 Suppression and Improves Fasting Lipids at Week 48 - (10/10/13) Higher Mortality With vs Without HIV After Acute Coronary, But Not With High CD4s - (10/10/13) "ART-naïve HIV+ adults, but not controls, had BMD loss at the total hip and trochanter sites over 48 weeks" - ART-Naive Adults More Likely to Lose Trochanter BMD Than HIV-Negatives - Writted by Mark Mascolini - (10/10/13) Program for Prescribers Cuts Antiretroviral Errors in Hospital Population - Writted by Mark Mascolini - (10/10/13) Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (10/10/13) Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (10/10/13) DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION: COMMAND GT 2/3 STUDY - (10/10/13) Causes of Death among People with Hepatitis C in NYC, 2000-2011 - (10/10/13) HIV/Hepatitis C (HCV) Co-infection among Men who have Sex with Men (MSM) in New York City (NYC), 2000-2010 - (10/10/13) Colorectal Cancer Screening 20% Less Likely With HIV in Large Medicaid Population - (10/10/13) Lack of HCV Genetic Diversity Tied to Higher Liver Disease Risk in Women With HIV - (10/07/13) High Referral of HCV Patients to Specialists But Low Treatment Initiation Rate - Barriers to Care & Treatment - (10/07/13) CDC Figures Annual US Mortality in People With HCV Could Top 80,000: HCV Mortality Under-reported, Mortality Rate 12 Times Higher than General Population, HCV+ Die 15 Years Younger than General Population - (10/07/13) Cumulative Viral Load Predicts Morbidity/Mortality in Perinatally Infected Children - written by Mark Mascolini - (10/07/13) Rash in 10% of Taiwanese Starting Once-Daily Darunavir--and 7% Dropout Rate - written by Mark Mascolini - (10/07/13) 15% of HIV+ Adults in NY Clinics Still Seronegative for Measles, Mumps, Rubella - written by Mark Mascolini - (10/07/13) Six-Month HIV Suppression Better With Single-Tablet Regimens Than Multitablet Combos - written by Mark Mascolini - (10/07/13) Low Risk but Twice Higher Risk of Suicidal Thoughts or Acts on First-Line Efavirenz - written by Mark Mascolini - (10/07/13) Lack of ART Tied to Tripled Mortality in Veterans With Community-Acquired Pneumonia - written by Mark Mascolini - (10/07/13) Sofosbuvir and Peginterferon Alfa-2a/Ribavirin for Treatment-Naïve Genotype 1-4 HCV-Infected Patients Who Are Coinfected With HIV - (10/07/13) Optimization of an Interferon-free Hepatitis C Virus Therapy Regimen Containing the HCV NS3/4A Protease Inhibitor Faldaprevir, the Non-nucleoside NS5B Inhibitor Deleobuvir, and Ribavirin for Genotype-1b-infected Patients - (10/07/13) Barriers to Hepatitis C Treatment in an HIV-HCV Co- Infected Cohort - (10/07/13) Telaprevir-based triple therapy for elderly patients with genotype 1 chronic hepatitis C - (10/07/13) Does Knowledge Influence Reporting Practices when Screening for Hepatitis C in Pregnant Women? - (10/07/13) Cumulative Viremia-Copy Years Predicts Morbidity and Mortality in Perinatally HIV-Infected Children - (10/07/13) Assessing Vitamin D Testing and Supplementation Patterns in a Large Inner City Clinic - (10/07/13) Current Alcohol and Substance Use in HIV-infected and HIV/HCV-co-infected Patients in Routine Clinical Care across the U.S. - (10/07/13) Single tablet regimens do not necessarily translate into more durable HIV treatments: "initial use of RAL-based regimens was associated with a better outcome........patients starting HAART with RAL were less likely to change regimen...... the main reason for 1st line discontinuation/switch remain the adverse effects, very few virological failure were observed" - (10/07/13) Pilot Study to Evaluate Intramyocardial Lipid Accumulation in HIV+ Patients Receiving Highly Active Antiretroviral Therapy (HAART) - (10/07/13) Long-Term Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Compared to Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected, Treatment-Naïve, Black Versus Non-Black Subjects - (10/07/13) STaR Study: Association of Efficacy Outcomes with Baseline HIV-1 RNA and CD4 Count and Adherence Rate for the Single-Tablet Regimens Rilpivirine/Emtricitabine/Tenofovir DF and Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults - (10/07/13) HIV+ Individuals on ART Are At Risk of Polypharmacy: More Medication Increases Mortality - (10/04/13) Comorbidity prevalence and its influence on non-ARV comedication burden among HIV positive patients - (10/04/13) Safety and Efficacy of Dolutegravir (DTG; GSK1349572) in Treatment-Experienced HIV-1 Infected Adolescents: 24-week Results from IMPAACT P1093 - (10/04/13) Outcomes Differ for HIV-Infected Patients Receiving Care at Hospital vs. Community-Based Clinics - (10/04/13) "The Clinical Role and Cost-effectiveness of Long-acting Antiretroviral Formulations" - Long-Acting ARV Formulations Could Improve Survival in People With Poor Adherence - written by Mark Mascolini - (10/04/13) Comorbidity Rate, Non-ARV Prescriptions Higher in HIV-Positives Than Matched Controls - written by Mark Mascolini - (10/04/13) Non-AIDS Death Rate Jumps From Early to Recent ART Era in Large Single-Site Study - written by Mark Mascolini - (10/04/13) Higher Intramyocardial Lipids in Antiretroviral-Treated Men Than in HIV-Negatives - written by Mark Mascolini - (10/04/13) Dolutegravir Effective at 24 Weeks in Adolescents Replacing Failing Regimen - written by Mark Mascolini - (10/04/13) Once-Daily Etravirine Effective Through 24 Weeks in Three-Center Study - written by Mark Mascolini - (10/04/13) Community or Hospital HIV Clinic? Patient Profiles, Outcomes Differ in 4-Year Study - written by Mark Mascolini - (10/04/13)